Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Triple receptor activity: GLP-1, GIP, and glucagon Appetite and satiety pathway support Energy expenditure and fat metabolism research Body weight reduction in clinical trials Potential metabolic health improvements A possible future option for clients who have plateaued on existing therapies In a phase 2 trial published in The New England Journal of Medicine, adults with obesity who received Retatrutide for 48 weeks had substantial reductions in body weight, with the 12 mg group showing a mean percentage change of -24.2% compared with -2.1% for placebo
Chronic psychosocial stress elevates cortisol, triggers comfort cravings, and counters appetite suppression
As a result, the peptide can stimulate insulin secretion, suppress glucagon secretion, slow gastric emptying, and reduce appetite
If you are interested in learning more about whether you may be a candidate for GLP-1 medications, we invite you to take our free assessment quiz
It has become popular due to its ease of use and promising results in reducing weight
